PATTERNS OF PRESCRIPTION AND ADR MONITORING OF DRUGS IN THE MANAGEMENT OF NEUROPATHIC PAIN IN A TERTIARY CARE TEACHING HOSPITAL
Objective: Neuropathic pain arises from demage, or the pathological changes in the peripheral or central nervous sytem. The pain is difficult to treat as standard treatment with conventional analgesics doesn`t typically provide effective relief of pain.
Methods: It was a one year study of utilization and analysis of prescriptions for PNDs (Painful neuropathic disorders). The parameters evaluated were demographic profile of the patient (age and gender), type and etiology of PNDs, drug data (name of the group of drugs with individual drugs, mono or polytherapy, number of drugs per prescription, formulation) and associated adverse drug reactions(ADR) with the prescribed drug.
Results: Maximum number of patients of PNDs resides in the age group of 18 â€“ 35 yrs (41.2%) & more common in females. The most common PND encountered was painful diabetic neuropathy (43.9%) followed by cervical and lumbar radiculopathy, post herpetic neuralgia. 2942 drugs were prescribed in 1020 prescriptions out of which, 96.8% were oral and 3.2% were topical formulations. Most frequently prescribed group of drug was tricyclic antidepressant (27.3%) followed by anticonvulsants (25.3%). Polypharmacy was seen 89.7% as compared to monotherapy (10.3%). Only 132 ADRs of various types were seen. The most common organ system affected was central nervous system followed by gastro intestinal systems. The most common drugs implicated for ADRs were TCAs (24.4%), anticonvulsants (16.6%), and Pregabeline (9.8%). There were no fatal adverse events. Mild to moderate ADRs included constipation, nausea, vomiting, drowsiness, dryness of mouth.
Conclusions: The choice of drug depends on etiology of neuropathic pain, drug efficacy and availability and also on ADR profile.
2. Fields HL, Martin JB. Pain: pathophysiology and management. In Harrisonâ€™s Principles of Internal Medicine. 14 editions. Edited by: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL. United States of America: McGraw-Hill Companies; 1997. p. 55-8.
3. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2 editions. Seattle: IASP Press; 1994.
4. Attal N, Cruccu G, Haanpaa M, Jensen TS, Nurmikko T, Sampaio C, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
5. Oâ€™Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122:S22-S32.
6. Attal N, Finnerup NB. On behalf of the IASP Neuropathic Pain Special Interest Group (NeuPSIG): pharmacological management of neuropathic pain. IASP 2010;18:1-8.
7. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with post herpetic neuralgia: results from a population-based survey. J Pain 2005;6(6):356-63.
8. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patientsâ€™ perspectives. J Pain 2006;7(12):892-900.
9. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results of a cross-sectional survey. Eur J Pain 2006;10(2):127-35.
10. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68(15):1178-82.
11. Oâ€™Connor AB. Neuropathic pain: a review of the quality of life impact, costs, and cost-effectiveness of therapy. Pharmacoeconomics 2009;27(2):95-112.
12. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5(3):143-9.
13. Dworkin RH, White R, Oâ€™Connor AB, Baser O, Hawkins K. Health care costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007;55(8):1168-75.
14. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 21;2009.
15. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27(9):1454-67.
16. Donaldson Sir L. The 2008 report of the Chief Medical Officer: 150 years of the Annual Report of the Chief Medical Officer: on the state of public health 2008. London, England: Department of Health, 2009. http://www.dh.gov.uk /en/Publicationsandstatistics/Publications/AnnualReports/DH_096206. Accessed 12;2010.
17. Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 2005;5:823-30.
18. Gillian C Hall, Steve V Morant, Dawn Carroll, Zahava L Gabriel, Henry J McQuay. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. Hall et al. BMC Family Practice 2013;14(28):2â€“10.
19. Freynhagen R, Baron R, Gockel U, TÅ¡lle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20.
20. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiol Scand 2008;52:132-6.
21. Hall GC, Carroll D, McQuay H. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam Pract 2008;9:26.
22. Lund C, Koskinen M, Suneetha S, et al. Histopathological and clinical findings in leprosy patients with chronic neuropathic pain: a study from Hyderabad, India. Lepr Rev 2007;78:369-80.
23. Hietaharju A, Croft R, Alam R, et al. Chronic neuropathic pain in treated leprosy. Lancet 2000;356:1080-81.
24. Gary A Walco, Robert H Dworkin, Elliot J Krane, Alyssa A Le Bel, Rolf-Detlef Treede, Dr Med. Neuropathic pain in children: special considerations Mayo Clin Proc 2010;85(3)(suppl):S33-S41.
25. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
26. Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59(Suppl 4):5-14.
27. Freynhagen R, Bennett M I. Diagnosis and management of neuropathic pain-Clinical Review. HIV Articles: BMJ 2009;339:b3002.
28. McCleane GJ. Anticonvulsants-epilepsy or pain? In Press Ulster Medical Journal.
29. Trousseau A. De la nevralgie Epileptiforme. Clin Med Hotel Dieu 1885;2:33-44.
30. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995;311:1047-52.
31. Kingery WS. A critical review of controlled trials for peripheral neuropathic pain and complex regional pain syndrome. Pain 1997;73:123-39.
32. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51.
33. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmikko T. European federation of neurological societies: efns guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113â€“e88.
34. Gilron I, Bailey JM. Trends in opioid use for chronic neuropathic pain: a survey of patients pursuing enrollment in clinical trials. Can J Anaesth 2003;50:42-7.
35. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.
36. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4(3):281-5.
37. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110(3):697-706.
38. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997;154(12):1760-2.